Physician profile
Stephen Soloway
NPI 1609997873
$12,448.58
in general payments reported to CMS, 2019-2025
25 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.05 · 2020: $150 · 2021: $33.09 · 2022: $164 · 2023: $5,853 · 2024: $5,798 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,250 · Travel and Lodging: $2,960 · Food and Beverage: $1,766 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,250.00 |
| Travel and Lodging | $2,960.00 |
| Food and Beverage | $1,766.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $5,423.56 | 2023 | |
| Amgen INC. | $5,091.32 | 2023-2025 | Uplizna, Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $616.70 | 2022-2025 | |
| Horizon Therapeutics Plc | $214.90 | 2019-2023 | Krystexxa, Uplizna |
| Glaxosmithkline, LLC. | $212.75 | 2023-2025 | Benlysta |
| Alexion Pharmaceuticals, INC. | $148.30 | 2022-2024 | Soliris, Ultomiris, Strensiq |
| Sobi, INC | $125.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $89.67 | 2019-2025 | Orencia |
| Zimmer Biomet Holdings, INC. | $70.61 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Ucb, INC. | $55.91 | 2022-2024 | Cimzia |
| Abbvie INC. | $51.79 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $49.93 | 2021-2024 | Lupkynis |
| Fresenius Kabi USA, LLC | $47.71 | 2023-2024 | Idacio |
| Pfizer INC. | $45.67 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.07 | 2023-2025 | Hyqvia, Vpriv |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $31.06 | 2024-2025 | |
| Catalyst Pharmaceuticals, INC. | $19.12 | 2022 | |
| Kyowa Kirin, INC. | $16.20 | 2025 | |
| Endo Pharmaceuticals INC. | $15.67 | 2024 | Xiaflex |
| Lundbeck LLC | $15.32 | 2023 | Vyepti |
| Ani Pharmaceuticals, INC. | $15.23 | 2024 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $15.03 | 2023 | Crysvita |
| Xeris Pharmaceuticals, INC. | $14.52 | 2022 | |
| Radius Health, INC. | $14.46 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Soloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.